Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I AZD2171 in Patients With Relapsed or Refractory AML and Elderly Patients With DeNovo or Secondary AML

NCT00502385 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00502385
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00502385 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I AZD2171 in Patients With Relapsed or Refractory AML and Elderly Patients With DeNovo or Secondary AML
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2004
Completion date
Not reported
Enrollment
54 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute, leukaemia, myelocytic